# William J. Sandborn

**Type:** Researchers  
**Canonical URL:** https://scholariq.org/researchers/william-j-sandborn/

## Facts

| Field | Value |
| --- | --- |
| Citations | 166,592 |
| Field | Inflammatory Bowel Disease |
| h-index | 200 |
| i10-index | 951 |
| Last Known Institution | University of San Diego |
| OpenAlex ID | https://openalex.org/A5032150391 |
| ORCID iD | https://orcid.org/0000-0002-3314-7960 |
| Works | 2,100 |

## Researcher papers

Showing 12 of 23.

- [Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/vedolizumab-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD](https://scholariq.org/papers/stride-ii-an-update-on-the-selecting-therapeutic-targets-in-inflammatory-bowel/)
- [Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target](https://scholariq.org/papers/selecting-therapeutic-targets-in-inflammatory-bowel-disease-stride-determining/)
- [Ustekinumab as Induction and Maintenance Therapy for Crohn’s Disease](https://scholariq.org/papers/ustekinumab-as-induction-and-maintenance-therapy-for-crohn-s-disease/)
- [Tofacitinib as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/tofacitinib-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Ustekinumab as Induction and Maintenance Therapy for Ulcerative Colitis](https://scholariq.org/papers/ustekinumab-as-induction-and-maintenance-therapy-for-ulcerative-colitis/)
- [Development of the Crohnʼs disease digestive damage score, the Lémann score](https://scholariq.org/papers/development-of-the-crohn-s-disease-digestive-damage-score-the-lemann-score/)
- [Effects of Adalimumab Therapy on Incidence of Hospitalization and Surgery in Crohn's Disease: Results From the CHARM Study](https://scholariq.org/papers/effects-of-adalimumab-therapy-on-incidence-of-hospitalization-and-surgery-in/)
- [Small-bowel imaging in Crohn's disease: a prospective, blinded, 4-way comparison trial](https://scholariq.org/papers/small-bowel-imaging-in-crohn-s-disease-a-prospective-blinded-4-way-comparison/)
- [Clinical course and costs of care for Crohn's disease: Markov model analysis of a population-based cohort](https://scholariq.org/papers/clinical-course-and-costs-of-care-for-crohn-s-disease-markov-model-analysis-of-a/)
- [Infliximab Reduces Endoscopic, but Not Clinical, Recurrence of Crohn’s Disease After Ileocolonic Resection](https://scholariq.org/papers/infliximab-reduces-endoscopic-but-not-clinical-recurrence-of-crohn-s-disease/)
- [Effect of Infliximab on Short-Term Complications in Patients Undergoing Operation for Chronic Ulcerative Colitis](https://scholariq.org/papers/effect-of-infliximab-on-short-term-complications-in-patients-undergoing/)

## Researcher topics

- [Inflammatory Bowel Disease](https://scholariq.org/topics/inflammatory-bowel-disease/)
- [Microscopic Colitis](https://scholariq.org/topics/microscopic-colitis/)
- [Autoimmune and Inflammatory Disorders](https://scholariq.org/topics/autoimmune-and-inflammatory-disorders/)
- [Biosimilars and Bioanalytical Methods](https://scholariq.org/topics/biosimilars-and-bioanalytical-methods/)
- [Eosinophilic Esophagitis](https://scholariq.org/topics/eosinophilic-esophagitis/)

## Researcher university

- [University of San Diego](https://scholariq.org/institutions/university-of-san-diego/)

---
Source: ScholarIQ — public research metadata, principally OpenAlex. See https://scholariq.org/sources/ for provenance and https://scholariq.org/methodology/ for what these figures mean.